According to the last reported balance sheet, AbbVie had liabilities of US$41.9b due within 12 months, and liabilities of ...

AbbVie Inc. closed $6.48 below its 52-week high ($199.95), which the company reached on September 3rd.

If you want to know who really controls AbbVie Inc. ( NYSE:ABBV ), then you'll have to look at the makeup of its share ...

We recently published a list of 10 Best Big-Name Stocks to Buy Right Now According to Short Sellers. In this article, we are ...

Strategically, the $21 billion deal for Pharmacyclics seems to make sense for AbbVie, but at least some analysts said the company had paid too much. With a $21 billion deal, the pharmaceutical ...

DBS analyst Mark Kong CFA has maintained their neutral stance on ABBV stock, giving a Hold rating on September 3. Mark Kong CFA has given his ...

AbbVie’s TV spots say all patients who take the drug, called Ubrelvy, can expect their migraine pain to be eliminated after a ...

AbbVie Inc (ABBV) stock saw a modest uptick, ending the day at $196.42 which represents a slight increase of $3.02 or 1.56% from the prior close of $193.4. The stock opened at $194.97 and touched a ...

AbbVie Inc . (NYSE:ABBV), a pharmaceutical company, has amended its bylaws, effective September 6, 2024. The changes were approved by the Board of Directors and include an update to the address of the ...

AbbVie Inc. (NYSE:ABBV) is a pharmaceutical company with strong exposure to immunology and oncology. AbbVie Inc. (NYSE:ABBV)’s next-generation immunology drugs, Skyrizi and Rinvoq, continue to ...